Elevated Transaminases as Predictors of COVID-19 Pneumonia Severity

Medicina (Kaunas). 2022 Jun 23;58(7):842. doi: 10.3390/medicina58070842.

Abstract

Background: This study aimed to calculate the frequency of elevated liver enzymes in hospitalized patients with coronavirus disease 2019 (COVID-19) infection and to test if liver enzyme biochemistry levels on admission could predict the computed tomography (CT) scan severity score of bilateral interstitial pneumonia.

Methods: This single-center study comprised of 323 patients including their demographic data, laboratory analyses, and radiological findings. All the information was taken from electronic health records, followed by statistical analysis.

Results: Out of 323 patients, 115 of them (35.60%) had aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) over 40 U/L on admission. AST was the best predictor of CT scan severity score of bilateral interstitial pneumonia (R2 = 0.313, Adjusted R2 = 0.299). CT scan severity score in the peak of the infection could be predicted with the value of AST, neutrophils, platelets, and monocytes count (R2 = 0.535, Adjusted R2 = 0.495).

Conclusion: AST, neutrophils, platelets, and monocytes count on admission can account for almost half (49.5%) of the variability in CT scan severity score at peak of the disease, predicting the extensiveness of interstitial pneumonia related to COVID-19 infection. Liver enzymes should be closely monitored in order to stratify COVID-19 patients with a higher risk of developing severe forms of the disease and to plan the beforehand step-up treatment.

Keywords: COVID-19; SARS-CoV-2; liver; transaminases.

MeSH terms

  • Alanine Transaminase
  • Aspartate Aminotransferases
  • COVID-19*
  • Humans
  • Pneumonia*
  • Retrospective Studies
  • SARS-CoV-2

Substances

  • Aspartate Aminotransferases
  • Alanine Transaminase

Grants and funding

This research received no external funding.